Cargando…

Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview

The high mortality rate associated with hepatocellular carcinoma (HCC) is partly due to the high proportion of patients who present with advanced stage disease at diagnosis, for whom there are limited treatment options. For selected patients with initially unresectable HCC, locoregional and/or syste...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Hui-Chuan, Zhu, Xiao-Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636437/ https://www.ncbi.nlm.nih.gov/pubmed/34869008 http://dx.doi.org/10.3389/fonc.2021.772195

Ejemplares similares

Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis
por: Chen, Xinyu, et al.
Publicado: (2021)

Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection
por: Chao, Jiashuo, et al.
Publicado: (2021)

Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma
por: Chen, Kang, et al.
Publicado: (2022)

Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
por: Li, Xingzhi, et al.
Publicado: (2023)

Successful conversion therapy for unresectable hepatocellular carcinoma is getting closer: A systematic review and meta-analysis
por: Pei, Yinxuan, et al.
Publicado: (2022)

Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study
por: Yi, Yong, et al.
Publicado: (2022)

Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy
por: Frankul, Leana, et al.
Publicado: (2021)

Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Li, Weiwei, et al.
Publicado: (2022)

Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction
por: Kamarajah, S. K., et al.
Publicado: (2020)

Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study
por: Zhang, Jinliang, et al.
Publicado: (2021)

Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib
por: Barbier, L., et al.
Publicado: (2011)

Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation
por: Biolato, Marco, et al.
Publicado: (2021)

Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study
por: Huang, Yun, et al.
Publicado: (2021)

Conversion Therapy of Large Unresectable Hepatocellular Carcinoma With Ipsilateral Portal Vein Tumor Thrombus Using Portal Vein Embolization Plus Transcatheter Arterial Chemoembolization
por: He, Chengjian, et al.
Publicado: (2022)

Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features
por: Wang, Si-Yuan, et al.
Publicado: (2023)

Downstaging and Conversation Strategy for Advanced Hepatocellular Carcinoma with Portal Vein Branch Tumor Thrombus: TACE, (125)I Seed Implantation, and RFA for Hepatocellular Carcinoma with Portal Vein Branch Tumor Thrombus
por: Zhao, Xiao-Hui, et al.
Publicado: (2023)

Efficacy of conversion therapy on initially unresectable locally advanced rectal cancer
por: Liu, Tianyu, et al.
Publicado: (2021)

Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new?
por: Zhang, Ze-Feng, et al.
Publicado: (2018)

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma
por: Gan, Leijuan, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined With Endoscopic Therapy Is Beneficial for Unresectable Hepatocellular Carcinoma With Esophagogastric Varices
por: Tao, Ziwen, et al.
Publicado: (2021)

Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2023)

Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma
por: Nabrinsky, Edward, et al.
Publicado: (2020)

Liver transplantation in hepatocellular carcinoma – should we perform downstaging?
por: Filipec Kanižaj, Tajana, et al.
Publicado: (2022)

Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma
por: Zhu, Xiao-Dong, et al.
Publicado: (2022)

Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study
por: Qu, Wei-Feng, et al.
Publicado: (2022)

Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors
por: Gao, Qimeng, et al.
Publicado: (2021)

Plasma arginase-1 as a predictive marker for early transarterial chemoembolization refractoriness in unresectable hepatocellular carcinoma
por: Xia, Wei-Li, et al.
Publicado: (2022)

Favourable outcome of pathologic downstaging by locoregional treatment for hepatocellular carcinoma in liver transplantation
por: Kim, Deok Gie, et al.
Publicado: (2019)

Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2020)

Case report and literature review: Conversion surgery for initially unresectable huge retroperitoneal liposarcoma after preoperative radiotherapy
por: Cheng, Sarah Hsin, et al.
Publicado: (2023)

Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging
por: Affonso, Breno Boueri, et al.
Publicado: (2019)

Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
por: Luo, Laihui, et al.
Publicado: (2022)

Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study
por: Wang, Lijun, et al.
Publicado: (2023)

Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
por: Qin, He-nan, et al.
Publicado: (2022)

Downstaging of Hepatocellular Carcinoma Prior to Liver Transplant: Is There a Role for Adjuvant Sorafenib in Locoregional Therapy?
por: Vagefi, Parsia A., et al.
Publicado: (2010)

Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report
por: Liu, Zhaobo, et al.
Publicado: (2020)

Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies
por: Sun, Weijing, et al.
Publicado: (2018)

Advances of Targeted Therapy for Hepatocellular Carcinoma
por: Niu, Mengke, et al.
Publicado: (2021)

Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy
por: Wu, Jia-Lin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eapb7jhq8oskk9ufhnspeeqpfs